From Liquid Biopsy to Drug Delivery: Application Logic and Compliance Essentials of Exosome Extraction Reagents

Special Requirements of Liquid Biopsy for Exosome Extraction Reagents

In the field of liquid biopsy, exosome extraction reagents are one of the key steps for obtaining reliable test results. Unlike cell culture supernatants, exosomes in clinical plasma or serum samples are present at low abundance, with many interfering substances and limited sample volume, which places higher demands on extraction reagents. It is generally believed that exosome extraction reagents suitable for liquid biopsy need to have good reproducibility, low sample consumption, and the ability to be adapted to automated workflows.

At the same time, the compatibility of the extraction procedure with downstream PCR, sequencing, or immunoassays is crucial. If reagent residues inhibit enzyme activity, they may affect detection sensitivity. Therefore, during method development, it is usually necessary to evaluate the performance of the extracted product on different detection platforms, rather than only looking at the particle count after extraction.

Purity and Activity Considerations in Drug Delivery Research

Exosomes are being widely studied as drug delivery vehicles, and the selection of their extraction reagents must balance purity, sterility, and functional integrity. Unlike simply analyzing exosome cargo, drug delivery research pays more attention to whether the exosome membrane structure is intact, whether surface proteins remain active, and whether they are suitable for drug loading procedures. Some extraction methods may introduce polymers or high concentrations of salts, which need to be addressed during subsequent buffer exchange.

For such research, the gentleness of the reagent's handling is more important than extraction speed. If the extraction process causes exosomes to rupture or aggregate, even if the yield is high, it may lose significance for functional evaluation. It is generally recommended to measure the particle size, zeta potential, and markers of exosomes before and after drug loading, respectively, to help assess the effects of the extraction and drug loading processes.

Compliance Boundaries Between Medical Devices and Research Reagents

In mainland China, exosome-related products used for clinical diagnosis or treatment may be subject to medical device or drug regulations, while exosome extraction reagents for research use are usually limited to laboratory research and must not be used for clinical diagnosis or treatment purposes. Related product promotion should avoid implying medical functions such as disease diagnosis, therapeutic efficacy, or health management. As industry practitioners, the positioning of "research reagents" and "medical devices" should be clearly distinguished.

For example, product materials may objectively describe uses such as "for exosome enrichment" or "suitable for cell culture supernatants," but expressions such as "improve" or "detect cancer" should not be used. If clinical evaluation is involved, verification and approval should be completed in accordance with medical device registration requirements. Companies should also pay attention to the compliance of labels, instructions, and advertising content, and avoid absolute wording.

Points to Consider When Selecting Suppliers

Whether clear product use descriptions and sample applicability information are provided, rather than vague "universal" statements.

Whether batch numbers, storage conditions, shelf life, and basic quality control data can be provided to facilitate users in establishing experimental records.

The responsiveness of technical support, especially whether reasonable suggestions can be given when special samples or downstream applications are involved.

Whether product packaging and shipping conditions are stable, avoiding repeated freeze-thaw cycles that affect reagent performance.

Overall, the application of exosome extraction reagents is extending from basic research to directions such as liquid biopsy and drug delivery, but the technical requirements and compliance requirements differ across scenarios. Selecting a suitable exosome extraction reagent requires considering sample characteristics, downstream objectives, and regulatory boundaries at the same time. Only by maintaining standardization and restraint in scientific research and product development can exosome extraction reagents better serve the long-term development of life sciences and in vitro diagnostics.